Molecular staging and the selection of therapy for non-small cell lung cancer.
The stage-specific selection of therapy is the standard for patients with non-small cell lung cancer. Investigation of the molecular biology of lung cancer has provided pathways and targets that may be used to improve the efficacy of therapy and improve the survival for patients with lung cancer.
D'Amico
Thomas A
TA
Division of Thoracic Surgery, Duke University Medical Center, Durham, NC 27710, USA. damic001@mc.duke.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000628:therapy; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D052246:Cyclooxygenase 2 Inhibitors